Form 4: Artelo Biosciences Director Acquires Stock Options

Connie Matsui, a director of Artelo Biosciences, acquired stock options exercisable for 1,750 shares of common stock on December 20, 2024.

Summary

• On December 20, 2024, Connie Matsui, a director of Artelo Biosciences, acquired stock options.
• The options are exercisable for 1,750 shares of Artelo Biosciences common stock at a price of $0.9476 per share.
• The options vest on the earlier of December 20, 2025, or the day before the next annual meeting of the Issuer's stockholders, contingent upon continued service as a Service Provider.
• The options expire on December 20, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard disclosure of stock option grant to a director.

Future Outlook

The vesting of the options is contingent upon the reporting person continuing to be a Service Provider.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's securities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, as the value of the options increases if the company's stock price appreciates.

Key Dates

Keywords

stock options, Form 4, director, ARTL, Artelo Biosciences, beneficial ownership